Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
SGLT2 Inhibitor AKI Incidence Evaluated
Diabetes Care; ePub 2017 Aug 21; Nadkarni, et al
SGLT2 inhibitors do not appear to increase the risk of acute kidney injury (AKI) in people with type 2 diabetes, according to a study involving >750 individuals. Participants—all of whom had diabetes—were from the Mount Sinai chronic kidney disease registry or Geisinger Health System. They were either SGLT inhibitor users (n=1,584) or non-users (n=1,584) Investigators looked at AKI incidence. Among the results:
- 4% of SGLT inhibitor users in the Mount Sinai cohort had an AKI event over a median of 14 months, vs 10% of nonusers.
- Users were 60% less likely than nonusers to experience an AKI event.
- 2% of SGLT inhibitor users in the Geisinger cohort had an AKI event, vs 5% of nonusers
- Users were 40% less likely than nonusers to experience an AKI event.
Citation:
Nadkarni G, Ferrandino R, Chang A, et al. Acute kidney injury in patients on SGLT2 inhibitors: A propensity-matched analysis. [Published online ahead of print August 21, 2017]. Diabetes Care. doi:10.2337/dc17-1011.